Skip to content
Screener

Replimune Group REPL Operating Cash Flow

Operating Cash Flow at other companies

Amgen logo
AmgenAMGN
$4B+75.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$813M-29.0%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
-$18.04M-109%
Regenxbio logo
RegenxbioRGNX
-$62.24M-26.1%
Immunome logo
ImmunomeIMNM
-$58.64M-10.5%
CG Oncology logo
CG OncologyCGON
-$46.41M-66.0%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemNine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Accrued expenses and other current liabilities(4,679)2,501
Operating lease liabilities(605)(533)
Other non-current liabilities(584)480
Net cash used in operating activities(224,183)(138,519)
Cash flows from investing activities:
Purchases of property, plant and equipment and software capitalization(4,218)(5,553)
Purchase of short-term investments(73,941)(331,953)
Proceeds from sales and maturities of short-term investments302,496321,410

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's operating cash flow?
Replimune Group (REPL) reported operating cash flow of -$65.96M in Q4 2025.
How has Replimune Group's operating cash flow changed year-over-year?
Replimune Group's operating cash flow decreased by 30.1% year-over-year, from -$50.71M to -$65.96M.
What is the long-term trend for Replimune Group's operating cash flow?
Over 3 years (2022 to 2025), Replimune Group's operating cash flow has grown at a 32.7% compound annual growth rate (CAGR), from -$82.18M to -$192.25M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Replimune Group's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude